{"clinical_study": {"@rank": "1", "required_header": {"download_date": "ClinicalTrials.gov processed this data on June 05, 2014", "link_text": "Link to the current ClinicalTrials.gov record.", "url": "http://clinicaltrials.gov/show/NCT02147561"}, "id_info": {"org_study_id": "191622-148", "nct_id": "NCT02147561"}, "brief_title": "A Safety and Efficacy Study of BOTOX\u00ae in Korean Adults With Chronic Migraine", "sponsors": {"lead_sponsor": {"agency": "Allergan", "agency_class": "Industry"}}, "source": "Allergan", "oversight_info": {"authority": "South Korea: Korea Food and Drug Administration (KFDA)", "has_dmc": "No"}, "brief_summary": {"textblock": "This study will evaluate the safety and efficacy of BOTOX\u00ae treatment in Korean adults with\n      chronic migraine."}, "overall_status": "Not yet recruiting", "start_date": "June 2014", "completion_date": {"@type": "Anticipated", "#text": "January 2015"}, "primary_completion_date": {"@type": "Anticipated", "#text": "January 2015"}, "phase": "Phase 4", "study_type": "Interventional", "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", "primary_outcome": {"measure": "Percentage of Patients with Adverse Events", "time_frame": "28 Days", "safety_issue": "No"}, "secondary_outcome": [{"measure": "Change from Baseline in Headache Impact Test-6 (HIT-6) Total Score", "time_frame": "Baseline, Day 28", "safety_issue": "No"}, {"measure": "Physician Global Assessment of Outcome on a 3-Point Scale", "time_frame": "Day 28", "safety_issue": "No"}], "number_of_arms": "1", "enrollment": {"@type": "Anticipated", "#text": "200"}, "condition": "Migraine Disorders", "arm_group": {"arm_group_label": "botulinum toxin Type A", "arm_group_type": "Experimental", "description": "Botulinum toxin Type A injected across specific head and neck muscles on Day 0."}, "intervention": {"intervention_type": "Biological", "intervention_name": "botulinum toxin Type A", "description": "Botulinum toxin Type A injected across specific head and neck muscles on Day 0.", "arm_group_label": "botulinum toxin Type A", "other_name": ["BOTOX\u00ae", "onabotulinumtoxinA"]}, "eligibility": {"criteria": {"textblock": "Inclusion Criteria:\n\n          -  Ethnically Korean with a diagnosis of chronic migraine\n\n        Exclusion Criteria:\n\n          -  Anticipated need for botulinum toxin treatment for any reason other than chronic\n             migraine during the study\n\n          -  Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral\n             sclerosis"}, "gender": "Both", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No"}, "overall_official": {"last_name": "Medical Director", "role": "Study Director", "affiliation": "Allergan"}, "overall_contact": {"last_name": "Allergan Inc.", "email": "clinicaltrials@allergan.com"}, "location": {"facility": {"address": {"city": "Seoul", "country": "Korea, Republic of"}}, "status": "Not yet recruiting"}, "location_countries": {"country": "Korea, Republic of"}, "verification_date": "May 2014", "lastchanged_date": "May 22, 2014", "firstreceived_date": "May 22, 2014", "responsible_party": {"responsible_party_type": "Sponsor"}, "is_fda_regulated": "Yes", "is_section_801": "Yes", "has_expanded_access": "No", "condition_browse": {"mesh_term": "Migraine Disorders"}, "intervention_browse": {"mesh_term": ["Botulinum Toxins, Type A", "Botulinum Toxins"]}}}